Mitoquinone - Antipodean Pharmaceuticals
Alternative Names: MitoQ; MitoQ10; Mitoquinol; MitoubiquinoneLatest Information Update: 02 Oct 2021
At a glance
- Originator Antipodean Pharmaceuticals
- Class Benzoquinones; Organophosphorus compounds
- Mechanism of Action Antioxidants; Hypoxia-inducible factor 1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis; Non-alcoholic fatty liver disease
- Discontinued Alzheimer's disease; Cancer; Chemotherapy-induced damage; Diabetes mellitus; Friedreich's ataxia; Hypertension; Ischaemia; Parkinson's disease; Retinal disorders
Most Recent Events
- 22 Sep 2015 No recent reports on development identified - Phase-II for Hepatic fibrosis (Prevention) in New Zealand (PO)
- 22 Sep 2015 No recent reports on development identified - Phase-II for Non-alcoholic fatty liver disease in United Kingdom (PO)
- 03 Jun 2008 US FDA approves IND application for mitoquinone in Liver diseases